Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

被引：0

作者：

Nobuaki Suzuki

Shoichi Hazama

Takeshi Nagasaka

Hiroaki Tanioka

Yasuo Iwamoto

Yuji Negoro

Masami Yamauchi

Michiya Kobayashi

Hiroshi Okuda

Noriaki Fujishima

Taku Nishimura

Naoki Yamanaka

Kazuhiro Toyota

Yoshiko Mori

Yuki Nakagami

Mototsugu Shimokawa

Hiroaki Nagano

Masazumi Okajima

机构：

[1] Yamaguchi University Graduate School of Medicine,Department of Gastroenterological, Breast and Endocrine Surgery

[2] Yamaguchi University School of Medicine,Department of Translational Research and Developmental Therapeutics Against Cancer

[3] Kawasaki Medical School,Department of Clinical Oncology

[4] Hiroshima City Hiroshima Citizens Hospital,Department of Medical Oncology

[5] Kochi Health Sciences Center,Department of Medical Oncology

[6] Hiroshima Prefectural Hospital,Division of Clinical Oncology

[7] Kochi Medical School Hospital,Cancer Treatment Center

[8] Onomichi General Hospital,Surgery and Endoscopic Surgery

[9] Fukuda Clinic of Internal Medicine,Department of Surgery

[10] Heart and Digestive,Department of Surgery

[11] Kokura Memorial Hospital,Department of Surgery

[12] Japanese Red Cross Yamaguchi Hospital,Department of Surgery

[13] National Hospital Organization Higashihiroshima Medical Center,Department of Gastroenterological Surgery

[14] Okayama University Graduate School of Medicine,Cancer Biostatistics Laboratory, Clinical Research Institute

[15] Dentistry and Pharmaceutical Sciences,Department of Surgery

[16] National Kyushu Cancer Center,undefined

[17] Hiroshima City Hiroshima Citizens Hospital,undefined

来源：

International Journal of Clinical Oncology | 2019年 / 24卷

关键词：

Bevacizumab; CAPIRI; Biweekly; Second line; mCRC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1223 / 1230

页数：7

共 50 条

[41] Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: A multicenter phase II study
Baek, JH
Kim, JG
Sohn, SK
Kim, DH
Lee, KB
Song, HS
Kwon, KY
Do, YR
Ryoo, HM
Bae, SH
Park, KU
Kim, MK
Lee, KH
Hyun, MS
Chung, HY
Yu, W
JOURNAL OF KOREAN MEDICAL SCIENCE, 2005, 20 (06) : 966 - 970
[42] Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: A phase II study
Zaniboni, A
Meriggi, F
Alghisi, A
Mutti, S
Distefano, L
Rizzi, A
Bettini, L
Simoncini, E
Marpicati, P
Montini, E
Marini, G
TUMORI, 1995, 81 (06) : 435 - 437
[43] Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
Eisen, Tim
Thomas, Jose
Miller, Wilson H., Jr.
Gore, Martin
Wolter, Pascal
Kavan, Petr
Lopez Martin, Jose A.
Lardelli, Pilar
MELANOMA RESEARCH, 2009, 19 (03) : 185 - 192
[44] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study
Honda, M.
Matsuda, C.
Tanaka, C.
Kondo, K.
Takahashi, T.
Kosugi, C.
Tokunaga, Y.
Takemoto, H.
Kim, H. M.
Sakamoto, J.
Oba, K.
Mishima, H.
ANNALS OF ONCOLOGY, 2018, 29 : 161 - 161
[45] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
He, Wen-zhuo
Jiang, Chang
Yi, Jiahong
Xue, Ju
Yin, Zhao-feng
Dong, Wen-jing
Xia, Liang-Ping
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment
Tsuji, Akihito
Yoshino, Takayuki
Yamanaka, Takeharu
Bando, Hideaki
Satake, Hironaga
Yamazaki, Kentaro
Taniguchi, Hiroya
Oki, Eiji
Kotaka, Masahito
Oba, Koji
Miyata, Yoshinori
Muro, Kei
Komatsu, Yoshito
Baba, Hideo
Kato, Takeshi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[47] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
Bennouna, Jaafar
Borg, Christophe
Delord, Jean-Pierre
Husseini, Faress
Trillet-Lenoir, Veronique
Faroux, Roger
Francois, Eric
Ychou, Marc
Goldwasser, Francois
Bouche, Olivier
Senellart, Helene
Kraemer, Sandrine
Douillard, Jean-Yves
CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
[48] Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study
Tsutsumi, Soichi
Ishibashi, Keiichiro
Uchida, Nobuyuki
Ojima, Hitoshi
Hosouchi, Yasuo
Yashuda, Naokuni
Kigure, Wakako
Yamauchi, Satoru
Asao, Takayuki
Ishida, Hideyuki
Kuwano, Hiroyuki
ONCOLOGY, 2012, 83 (03) : 151 - 157
[49] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
Suzuki, Takeshi
Shinozaki, Eiji
Osumi, Hiroki
Nakayama, Izuma
Ota, Yumiko
Ichimura, Takashi
Ogura, Mariko
Wakatsuki, Takeru
Ooki, Akira
Takahari, Daisuke
Suenaga, Mitsukuni
Chin, Keisho
Yamaguchi, Kensei
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
[50] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
Mitsukuni Suenaga
Satoshi Matsusaka
Masashi Ueno
Noriko Yamamoto
Eiji Shinozaki
Nobuyuki Mizunuma
Toshiharu Yamaguchi
Kiyohiko Hatake
Surgery Today, 2011, 41 : 1067 - 1074

← 1 2 3 4 5 →